Linical Co., Ltd. (2183.T)
JPY 291.0
(-1.02%)
JPY 291.0
(-1.02%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -4.46 Billion JPY | -27.53% |
| 2022 | -3.49 Billion JPY | -86.06% |
| 2021 | -1.88 Billion JPY | -380.25% |
| 2020 | -391.69 Million JPY | 30.23% |
| 2019 | -561.43 Million JPY | -69.07% |
| 2018 | -332.07 Million JPY | 92.17% |
| 2017 | -4.23 Billion JPY | -29.2% |
| 2016 | -3.28 Billion JPY | -93.45% |
| 2015 | -1.69 Billion JPY | -4871.66% |
| 2014 | -34.12 Million JPY | 97.06% |
| 2013 | -1.15 Billion JPY | -6.3% |
| 2012 | -1.09 Billion JPY | -168.53% |
| 2011 | -406.33 Million JPY | -791.69% |
| 2010 | 58.74 Million JPY | 111.72% |
| 2009 | -501.15 Million JPY | -21.43% |
| 2008 | -412.7 Million JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -4.94 Billion JPY | -4.25% |
| 2023 Q2 | -4.1 Billion JPY | -43.59% |
| 2023 FY | -4.46 Billion JPY | -27.53% |
| 2023 Q4 | -4.46 Billion JPY | -3.56% |
| 2023 Q3 | -4.3 Billion JPY | -4.93% |
| 2023 Q1 | -2.86 Billion JPY | 18.27% |
| 2022 Q1 | -2.03 Billion JPY | -8.24% |
| 2022 Q2 | -2.46 Billion JPY | -21.23% |
| 2022 Q3 | -3.07 Billion JPY | -24.51% |
| 2022 Q4 | -3.49 Billion JPY | -13.88% |
| 2022 FY | -3.49 Billion JPY | -86.06% |
| 2021 Q2 | -866.52 Million JPY | -113.3% |
| 2021 Q1 | -406.25 Million JPY | -3.72% |
| 2021 Q3 | -1.32 Billion JPY | -52.34% |
| 2021 Q4 | -1.88 Billion JPY | -42.51% |
| 2021 FY | -1.88 Billion JPY | -380.25% |
| 2020 FY | -391.69 Million JPY | 30.23% |
| 2020 Q2 | 193.79 Million JPY | 848.57% |
| 2020 Q1 | -25.88 Million JPY | 95.39% |
| 2020 Q3 | 505.3 Million JPY | 160.74% |
| 2020 Q4 | -391.69 Million JPY | -177.52% |
| 2019 FY | -561.43 Million JPY | -69.07% |
| 2019 Q4 | -561.43 Million JPY | -346.44% |
| 2019 Q1 | 792.64 Million JPY | 338.69% |
| 2019 Q3 | 227.81 Million JPY | 317.6% |
| 2019 Q2 | -104.69 Million JPY | -113.21% |
| 2018 Q1 | -636.38 Million JPY | 84.99% |
| 2018 FY | -332.07 Million JPY | 92.17% |
| 2018 Q4 | -332.07 Million JPY | -254.87% |
| 2018 Q3 | -93.57 Million JPY | 89.05% |
| 2018 Q2 | -854.7 Million JPY | -34.31% |
| 2017 Q4 | -4.23 Billion JPY | -17.75% |
| 2017 Q1 | -2.87 Billion JPY | 12.38% |
| 2017 FY | -4.23 Billion JPY | -29.2% |
| 2017 Q2 | -3.43 Billion JPY | -19.37% |
| 2017 Q3 | -3.6 Billion JPY | -4.9% |
| 2016 Q4 | -3.28 Billion JPY | -55.33% |
| 2016 Q1 | -1.26 Billion JPY | 25.39% |
| 2016 FY | -3.28 Billion JPY | -93.45% |
| 2016 Q2 | -1.82 Billion JPY | -44.18% |
| 2016 Q3 | -2.11 Billion JPY | -15.78% |
| 2015 Q2 | -1.19 Billion JPY | -152.6% |
| 2015 Q4 | -1.69 Billion JPY | -14.64% |
| 2015 Q1 | -472.4 Million JPY | -1284.54% |
| 2015 FY | -1.69 Billion JPY | -4871.66% |
| 2015 Q3 | -1.47 Billion JPY | -24.0% |
| 2014 FY | -34.12 Million JPY | 97.06% |
| 2014 Q1 | -1.06 Billion JPY | 8.08% |
| 2014 Q4 | -34.12 Million JPY | -110.95% |
| 2014 Q3 | 311.69 Million JPY | 128.34% |
| 2014 Q2 | -1.1 Billion JPY | -3.17% |
| 2013 Q3 | -909.27 Million JPY | -7.39% |
| 2013 Q4 | -1.15 Billion JPY | -27.56% |
| 2013 FY | -1.15 Billion JPY | -6.3% |
| 2013 Q1 | -774.04 Million JPY | 29.06% |
| 2013 Q2 | -846.68 Million JPY | -9.38% |
| 2012 Q1 | -351.44 Million JPY | 13.51% |
| 2012 Q2 | -804.17 Million JPY | -128.82% |
| 2012 Q3 | -753.85 Million JPY | 6.26% |
| 2012 Q4 | -1.09 Billion JPY | -44.74% |
| 2012 FY | -1.09 Billion JPY | -168.53% |
| 2011 Q1 | 164.49 Million JPY | 180.01% |
| 2011 FY | -406.33 Million JPY | -791.69% |
| 2011 Q2 | 32.51 Million JPY | -80.23% |
| 2011 Q3 | -211.01 Million JPY | -749.0% |
| 2011 Q4 | -406.33 Million JPY | -92.56% |
| 2010 Q3 | -10.01 Million JPY | 97.37% |
| 2010 Q4 | 58.74 Million JPY | 686.76% |
| 2010 FY | 58.74 Million JPY | 111.72% |
| 2010 Q2 | -380.82 Million JPY | 0.0% |
| 2009 Q1 | -296.17 Million JPY | 28.24% |
| 2009 FY | -501.15 Million JPY | -21.43% |
| 2009 Q4 | -501.15 Million JPY | -5.85% |
| 2009 Q3 | -473.44 Million JPY | -12.62% |
| 2009 Q2 | -420.37 Million JPY | -41.94% |
| 2008 Q4 | -412.7 Million JPY | 0.0% |
| 2008 FY | -412.7 Million JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 700.907% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | -293.608% |
| GNI Group Ltd. | -17.93 Billion JPY | 75.112% |
| Trans Genic Inc. | -221.16 Million JPY | -1918.045% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | -1.576% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 6.821% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 411.348% |
| AnGes, Inc. | -3.79 Billion JPY | -17.525% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -960.65% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 117.919% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -795.966% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -857.075% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | -64.933% |
| CanBas Co., Ltd. | -1.88 Billion JPY | -136.378% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | -354.444% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | -31.388% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | -331.422% |
| Kidswell Bio Corporation | 343.58 Million JPY | 1399.02% |
| PeptiDream Inc. | 3.29 Billion JPY | 235.58% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | -358.906% |
| Ribomic Inc. | -2.09 Billion JPY | -112.564% |
| SanBio Company Limited | -3.78 Billion JPY | -17.774% |
| Healios K.K. | -2.19 Billion JPY | -103.803% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -372.376% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | -70.085% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | -214.968% |
| StemRIM | -8.41 Billion JPY | 46.929% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 4.701% |
| FunPep Company Limited | -1.79 Billion JPY | -148.876% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | -108.908% |
| Stella Pharma Corporation | -1.11 Billion JPY | -298.72% |
| TMS Co., Ltd. | -3.44 Billion JPY | -29.497% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 19.663% |
| Cuorips Inc. | -5.56 Billion JPY | 19.74% |
| K Pharma,Inc. | -3.26 Billion JPY | -36.642% |
| Takara Bio Inc. | -32.2 Billion JPY | 86.14% |
| ReproCELL Incorporated | -2.93 Billion JPY | -51.861% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -575.274% |
| StemCell Institute Inc. | -2.83 Billion JPY | -57.338% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | -115.999% |
| CellSeed Inc. | -2.01 Billion JPY | -121.829% |